A PET scan tested to tell radiation damage from tumor growth in brain metastases
Official title: Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing whether a special scan can tell if a spot in the brain is tumor growth or damage from radiation treatment.
Read our full plain-language summary
What the trial team says
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
Key facts
- Registry number
- NCT07511933
- Stage of testing
- Not applicable
- Conditions studied
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
Where it is running
This trial lists 1 site.
-
Netherlands
- Netherlands Cancer Institute - Antoni van Leeuwenhoek (Amsterdam)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.